Different viral agents are associated with an increased risk of more severe disease course and respiratory complications in immunocompromised patients.[@R1] The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) responsible for a severe acute respiratory syndrome (SARS) represents a source of concern for the management of patients with inflammatory rheumatic diseases. Lombardy is the region in Northern Italy with the highest incidence of COVID-19 cases, with more than 33 000 confirmed patients and 1250 requiring admission to the intensive care unit within 1 month. Since the first reports of COVID-19 cases in Italy, we have circulated a survey with a 2-week follow-up contact to patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) followed up at our biological outpatient clinic in Pavia, Lombardy. The survey investigated the patients' health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of the DMARDs during the first few weeks of pandemic. All patients had provided their informed consent for the use of personal and clinical data for scientific purposes, and no patient refused to participate.

During the first month, we have collected information on 320 patients (female 68%, mean age 55±14 years) treated with bDMARDs or tsDMARDs (57% with rheumatoid arthritis, 43% with spondyloarthritis, 52% treated with tumour necrosis factor inhibitors, 40% with other bDMARDs and 8% with tsDMARDs). As shown in [table 1](#T1){ref-type="table"}, four were confirmed cases of COVID-19 identified through rhinopharyngeal swabs. Another four patients reported symptoms which were highly suggestive of COVID-19. Five additional patients with reported certain contacts remained asymptomatic at the end of the 2-week observation period.

###### 

Clinical characteristics of the patients with confirmed or suspected COVID-19

                                      Confirmed COVID-19   Clinical picture highly suggestive of COVID-19   Contact with a known COVID-19 patient
  ----------------------------------- -------------------- ------------------------------------------------ ---------------------------------------
  Number of patients                  4                    4                                                5
  Age (years) (mean±SD)               58±5                 56±8                                             54±12
  Female, n (%)                       4 (100)              3 (75)                                           4 (80)
  Comorbidities, n (%)                                                                                       
   Hypertension                       1 (25)               2 (50)                                           1 (20)
   Diabetes                           0                    0                                                0
   Cardiovascular disease             0                    0                                                1 (20)
   Other                              4 (100)              4 (100)                                          3 (60)
  Smoking, n (%)                                                                                             
   Active                             1 (25)               0                                                0
   Previous                           2 (50)               3 (75)                                           1 (20)
  Rheumatological diagnosis                                                                                  
   RA, n (%)                          3 (75)               3 (75)                                           5 (100)
   SpA/PA,\* n (%)                    1 (25)               1\* (25)                                         0
  Rheumatological treatment, n (%)                                                                          
   bDMARD                                                                                                    
    Adalimumab                        0                    0                                                1 (20)
    Etanercept                        2 (50)               2 (50)                                           0
    Abatacept                         1 (25)               1 (25)                                           0
    Tocilizumab                       0                    0                                                1 (20)
   tsDMARD                                                                                                   
    Tofacitinib                       1 (25)               0                                                1 (20)
    Baricitinib                       0                    1 (25)                                           2 (40)
   Concomitant csDMARD                                                                                       
    Methotrexate                      2 (50)               1 (25)                                           3 (60)
    Leflunomide                       1 (25)               0                                                1 (20)
    Sulfasalazine                     0                    1 (25)                                           0
  Concomitant hydroxychloroquine      1 (25)               2 (50)                                           2 (40)
  Low-dose glucocorticoids\*          2 (50)               2 (50)                                           2 (40)
  Known contact with COVID-19         0                    1 (25)                                           5 (100)
  Symptoms, n (%)                                                                                           
   Fever                              4 (100)              1 (25)                                           0
   Non-productive cough               3 (75)               2 (50)                                           0
   Sputum production                  1 (25)               0                                                0
   Rhinorrhea                         2 (50)               1 (25)                                           0
   Sore throat                        0                    0                                                0
   Fatigue                            4 (100)              2 (50)                                           0
   Myalgia                            2 (50)               1 (25)                                           0
   Arthralgia                         1 (25)               1 (25)                                           0
   Anosmia/dysgeusia                  3 (75)               3 (75)                                           0
   Dyspnoea at rest                   1 (25)               0                                                0
   Dyspnoea on exertion               2 (50)               1 (25)                                           0
   Headache                           2 (50)               0                                                0
   Diarrhoea                          1 (25)               0                                                0
   Nausea/vomiting                    0                    0                                                0
  Chest X-ray performed               4 (100)              0†                                               0
  Chest X-ray pathological findings   0                    0                                                0
  Hospital admission                  1 (25)               0                                                0

\*Glucocorticoids≤5 mg/day prednisone equivalent.

†Subject to home quarantine.

bDMARD, biological disease-modifying antirheumatic drug; COVID-19, coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; PA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.

All patients with confirmed COVID-19 received at least one antibiotic course, and the hospitalised patient also received antiviral therapy and hydroxychloroquine. Overall, five patients were on previous stable treatment with hydroxychloroquine. All patients with symptoms of infection temporarily withdrew the bDMARD or tsDMARD at the time of symptom onset. To date, there have been no significant relapses of the rheumatic disease. None of the patients with a confirmed diagnosis of COVID-19 or with a highly suggestive clinical picture developed severe respiratory complications or died. Only one patient, aged 65, required admission to hospital and low-flow oxygen supplementation for a few days.

Our findings do not allow any conclusions on the incidence rate of SARS-CoV-2 infection in patients with rheumatic diseases, nor on the overall outcome of immunocompromised patients affected by COVID-19. A high level of vigilance and strict follow-up should be maintained on these patients, including the exclusion of superimposed infections. However, our preliminary experience shows that patients with chronic arthritis treated with bDMARDs or tsDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population.

These findings are not surprising as the severe respiratory complications caused by coronaviruses are thought to be driven by the aberrant inflammatory and cytokine response perpetuated by the host immune system.[@R4] During different coronavirus outbreaks, such as SARS and Middle East respiratory syndrome, there has been no increased mortality reported in patients undergoing immunosuppression for organ transplantation, cancer or autoimmune diseases.[@R3] Accordingly, among 700 patients admitted for severe COVID-19 at our hospital (a referral centre for SARS-CoV-2 infection) during last month, none was receiving bDMARDs or tsDMARDs.

Although continuous surveillance of patients with rheumatic diseases receiving immunosuppressive drugs is warranted, these data can support rheumatologists for the management and counselling of their patients, avoiding the unjustifiable preventive withdrawal of DMARDs, which could lead to an increased risk of relapses and morbidity from the chronic rheumatological condition.
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